Metabasis Therapeutics, Promising Preclinical Results with Its Novel Glucagon Antagonist for the Treatment of Type 2 Diabetes

Sept. 17, 2007--Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced that a poster entitled "A Novel Glucagon Antagonist Inhibits Glucagon-Stimulated Glucose Production in Human Hepatocytes and Lowers Blood Glucose in Animal Models of Type 2 Diabetes" was presented during the 43rd Annual Meeting of the European Association for the Study of Diabetes (Amsterdam, The Netherlands). The poster provides data from several preclinical studies that show a class of small molecule glucagon antagonists discovered by Metabasis has demonstrated promising glucose lowering activity in various animal models of type 2 diabetes... Metabasis Therapeutics' Press Release -